SG&A Spending Patterns: Pfizer Inc. vs. MorphoSys AG

A Decade of Financial Insights

Over the past decade, the pharmaceutical giants Pfizer Inc. and MorphoSys AG have showcased distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have consistently hovered around the $14 billion mark, reflecting a stable financial strategy. In contrast, MorphoSys AG has experienced a dramatic increase, with expenses surging by over 900% from 2014 to 2020, before stabilizing in recent years.

Key Insights

• Pfizer Inc.: Despite fluctuations in the pharmaceutical market, Pfizer's SG&A expenses have remained relatively stable, indicating a robust financial management strategy.
• MorphoSys AG: The significant rise in SG&A expenses, particularly between 2018 and 2020, suggests aggressive expansion or increased operational costs.

These insights provide a fascinating glimpse into the financial strategies of two leading pharmaceutical companies, highlighting their unique approaches to managing operational expenses.